Nandrone

There are possible estrogenic side effects of Nandrolone despite it not being a very estrogenic hormone, at least not directly. Nandrolone does aromatize slightly. Aromatization refers to the conversion of testosterone to estrogen . This takes place when the testosterone hormone interacts with the aromatase enzyme. When the conversion takes place this can cause estrogen levels to go up, which can promote gynecomastia and water retention. High blood pressure can also become an issue if water retention becomes severe. Along with the low level of aromatase activity Nandrolone is also a progestin and has a strong binding affinity for the progesterone receptor. This may stimulate the mammary tissue and enhance the risk of gynecomastia in sensitive individuals.

Combating the estrogenic side effects of Nandrolone can be achieved by the use of anti-estrogen medications, specifically Aromatase Inhibitors (AI’s) such as Anastrozole ( Arimidex ). Selective Estrogen Receptor Modulators (SERM’s) are also sometimes used, such as Tamoxifen ( Nolvadex ). However, AI’s are the proper choice as they will directly reduce serum estrogen levels and SERM’s will not. An AI should be enough to reduce and avoid gynecomastia unless the individual already has existing gynecomastia that could potentially be exasperated.

Important Note: It’s often been said that Nandrolone based gynecomastia is based on increases in prolactin. It is true that 19-nor steroids can increase prolactin, which can also negatively affect libido and erection function. Some men may need to use a dopamine agonist to combat this. However, it is not prolactin that causes 19-nor based gynecomastia but rather the imbalance between estrogen and progesterone. If you merely combat prolactin you may find yourself with the very gynecomastia you tried to avoid.
 

Using a randomized "double-blind" "placebo-controlled" design, 16 experienced male bodybuilders (age: 19-44 yr) either received ND (200 (-1), intramuscularly) or placebo for 8 wk. Body composition was assessed using the four-component model, combining results from underwater weighing, dual-energy x-ray absorptiometry (DXA), and deuterium dilution. Total bone mineral content and density were measured using DXA. Water compartments (extracellular water [ECW] and intracellular water [ICW]) were determined using deuterium dilution and bromide dilution.

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma.  If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease.  Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids.  Edema may occur occasionally with or without congestive heart failure.  Concomitant administration of adrenal steroids or ACTH may add to the edema.  In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth.  This adverse effect may result in compromised adult stature.  The younger the child the greater the risk of compromising final mature height.   The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.  This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

Nandrone

nandrone

Media:

nandronenandronenandronenandronenandrone